Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride

Lucy J. Schmidt, Karla V. Ballman, Donald J. Tindall

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

PURPOSE. With malignant progression to androgen independence, prostate cancer cells develop resistance to apoptosis and exhibit a variety of gene expression changes, including increased fatty acid synthase (FASN) expression. Increased FASN expression has been shown to correlate with poor prognosis, and correspondingly, the FASN gene has been proposed as a therapeutic target. Because FASN is an androgen regulated gene in the prostate, we have examined the effects of dutasteride on FASN in prostate cancer cells in vitro. Dutasteride is a novel dual inhibitor of the 5 alpha-reductase enzymes and is currently in use both for treatment of benign prostate hyperplasia (BPH) and in the reduction by dutasteride of prostate cancer events (REDUCE) prostate cancer prevention trial. METHODS. Microarray analysis was used to identify genes affected by treatment with dutasteride, followed by real time PCR confirmation. FASN expression at the protein level was examined using Western blotting and immunocytochemistry. Enzymatic activity of FASN was assayed by 14C-labeled malonyl-CoA incorporation. Viability after dutasteride treatment was assayed by MTS (Promega) and apoptosis via caspase 3/7 by DEVD cleavage assay. RESULTS. We have demonstrated that the 5 alpha-reductase inhibitor dutasteride, at clinically relevant levels, inhibits FASN mRNA, protein expression and enzymatic activity in prostate cancer cells. CONCLUSIONS. This is the first study to examine the effects of clinically relevant levels of dutasteride on prostate cancer cells at the molecular level and specifically, demonstrating the inhibition of FASN in these cells.

Original languageEnglish (US)
Pages (from-to)1111-1120
Number of pages10
JournalProstate
Volume67
Issue number10
DOIs
StatePublished - Jul 1 2007

Fingerprint

Fatty Acid Synthases
Prostatic Neoplasms
5-alpha Reductase Inhibitors
Androgens
Prostate
Apoptosis
Malonyl Coenzyme A
Genes
Caspase 7
Dutasteride
Therapeutics
Microarray Analysis
Caspase 3
Hyperplasia
Real-Time Polymerase Chain Reaction
Proteins
Western Blotting
Immunohistochemistry
Gene Expression
Messenger RNA

Keywords

  • Chemoprevention
  • Fatty acid synthase
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. / Schmidt, Lucy J.; Ballman, Karla V.; Tindall, Donald J.

In: Prostate, Vol. 67, No. 10, 01.07.2007, p. 1111-1120.

Research output: Contribution to journalArticle

Schmidt, LJ, Ballman, KV & Tindall, DJ 2007, 'Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride', Prostate, vol. 67, no. 10, pp. 1111-1120. https://doi.org/10.1002/pros.20602
Schmidt, Lucy J. ; Ballman, Karla V. ; Tindall, Donald J. / Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. In: Prostate. 2007 ; Vol. 67, No. 10. pp. 1111-1120.
@article{1aee1571685645f79bd26a0a1955e129,
title = "Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride",
abstract = "PURPOSE. With malignant progression to androgen independence, prostate cancer cells develop resistance to apoptosis and exhibit a variety of gene expression changes, including increased fatty acid synthase (FASN) expression. Increased FASN expression has been shown to correlate with poor prognosis, and correspondingly, the FASN gene has been proposed as a therapeutic target. Because FASN is an androgen regulated gene in the prostate, we have examined the effects of dutasteride on FASN in prostate cancer cells in vitro. Dutasteride is a novel dual inhibitor of the 5 alpha-reductase enzymes and is currently in use both for treatment of benign prostate hyperplasia (BPH) and in the reduction by dutasteride of prostate cancer events (REDUCE) prostate cancer prevention trial. METHODS. Microarray analysis was used to identify genes affected by treatment with dutasteride, followed by real time PCR confirmation. FASN expression at the protein level was examined using Western blotting and immunocytochemistry. Enzymatic activity of FASN was assayed by 14C-labeled malonyl-CoA incorporation. Viability after dutasteride treatment was assayed by MTS (Promega) and apoptosis via caspase 3/7 by DEVD cleavage assay. RESULTS. We have demonstrated that the 5 alpha-reductase inhibitor dutasteride, at clinically relevant levels, inhibits FASN mRNA, protein expression and enzymatic activity in prostate cancer cells. CONCLUSIONS. This is the first study to examine the effects of clinically relevant levels of dutasteride on prostate cancer cells at the molecular level and specifically, demonstrating the inhibition of FASN in these cells.",
keywords = "Chemoprevention, Fatty acid synthase, Prostate cancer",
author = "Schmidt, {Lucy J.} and Ballman, {Karla V.} and Tindall, {Donald J.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1002/pros.20602",
language = "English (US)",
volume = "67",
pages = "1111--1120",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride

AU - Schmidt, Lucy J.

AU - Ballman, Karla V.

AU - Tindall, Donald J.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - PURPOSE. With malignant progression to androgen independence, prostate cancer cells develop resistance to apoptosis and exhibit a variety of gene expression changes, including increased fatty acid synthase (FASN) expression. Increased FASN expression has been shown to correlate with poor prognosis, and correspondingly, the FASN gene has been proposed as a therapeutic target. Because FASN is an androgen regulated gene in the prostate, we have examined the effects of dutasteride on FASN in prostate cancer cells in vitro. Dutasteride is a novel dual inhibitor of the 5 alpha-reductase enzymes and is currently in use both for treatment of benign prostate hyperplasia (BPH) and in the reduction by dutasteride of prostate cancer events (REDUCE) prostate cancer prevention trial. METHODS. Microarray analysis was used to identify genes affected by treatment with dutasteride, followed by real time PCR confirmation. FASN expression at the protein level was examined using Western blotting and immunocytochemistry. Enzymatic activity of FASN was assayed by 14C-labeled malonyl-CoA incorporation. Viability after dutasteride treatment was assayed by MTS (Promega) and apoptosis via caspase 3/7 by DEVD cleavage assay. RESULTS. We have demonstrated that the 5 alpha-reductase inhibitor dutasteride, at clinically relevant levels, inhibits FASN mRNA, protein expression and enzymatic activity in prostate cancer cells. CONCLUSIONS. This is the first study to examine the effects of clinically relevant levels of dutasteride on prostate cancer cells at the molecular level and specifically, demonstrating the inhibition of FASN in these cells.

AB - PURPOSE. With malignant progression to androgen independence, prostate cancer cells develop resistance to apoptosis and exhibit a variety of gene expression changes, including increased fatty acid synthase (FASN) expression. Increased FASN expression has been shown to correlate with poor prognosis, and correspondingly, the FASN gene has been proposed as a therapeutic target. Because FASN is an androgen regulated gene in the prostate, we have examined the effects of dutasteride on FASN in prostate cancer cells in vitro. Dutasteride is a novel dual inhibitor of the 5 alpha-reductase enzymes and is currently in use both for treatment of benign prostate hyperplasia (BPH) and in the reduction by dutasteride of prostate cancer events (REDUCE) prostate cancer prevention trial. METHODS. Microarray analysis was used to identify genes affected by treatment with dutasteride, followed by real time PCR confirmation. FASN expression at the protein level was examined using Western blotting and immunocytochemistry. Enzymatic activity of FASN was assayed by 14C-labeled malonyl-CoA incorporation. Viability after dutasteride treatment was assayed by MTS (Promega) and apoptosis via caspase 3/7 by DEVD cleavage assay. RESULTS. We have demonstrated that the 5 alpha-reductase inhibitor dutasteride, at clinically relevant levels, inhibits FASN mRNA, protein expression and enzymatic activity in prostate cancer cells. CONCLUSIONS. This is the first study to examine the effects of clinically relevant levels of dutasteride on prostate cancer cells at the molecular level and specifically, demonstrating the inhibition of FASN in these cells.

KW - Chemoprevention

KW - Fatty acid synthase

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=34250843751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250843751&partnerID=8YFLogxK

U2 - 10.1002/pros.20602

DO - 10.1002/pros.20602

M3 - Article

C2 - 17477363

AN - SCOPUS:34250843751

VL - 67

SP - 1111

EP - 1120

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 10

ER -